Discontinued — last reported Q4 '23

Products & Services · Intangible asset impairments

Etrasimod (Velsipity) — Intangible asset impairments

Pfizer Etrasimod (Velsipity) — Intangible asset impairments remained flat by 0.0% to $350.00M in Q4 2023 compared to the prior quarter.

Analysis

StatementSegment
First reportedQ1 2023
Last reportedQ4 2023Feb 26, 2026
Rolls up toImpairment Charges
Metric ID: pfe_segment_etrasimod_velsipity_intangible_asset_impairments

Historical Data

1 years
 FY'23
Value$1.40B

Frequently Asked Questions

What is Pfizer's etrasimod (velsipity) — intangible asset impairments?
Pfizer (PFE) reported etrasimod (velsipity) — intangible asset impairments of $350.00M in Q4 2023.